Industry Sectors
Life Sciences & Healthcare
"responsive, fast and able to recognise the urgency of matters."
At KG we guide our clients in the life sciences & healthcare industry through the legal, compliance and regulatory aspects that affect their business, both strategically as well as in their day-to-day operations. Our experience extends to all legal issues related to pharmaceutical products, medical devices and sanitary material, vaccines, biotechnology, pharmaceutical cannabis products, cosmetics, veterinary products, medical nutrition, food for special medical purpose, biocides and chemical reagents.
Main Areas of focus include, inter alia:
- Assistance in strategic transactions – manufacturing, distribution/co-distribution, storage, joint venture, branding, outsourcing, research, clinical trial, collaboration, co-promotion and other types of commercial agreements;
- Negotiation of contracts;
- Distribution channels and market access methods – redesigning of local distribution networks;
- Pricing and reimbursement policies – reimbursement strategies for new services, products and technologies, discounts schemes and other reimbursement solutions for patients;
- Discounting and rebating schemes – Clawback and Rebate;
- Tax considerations and implications of contemplated strategies and projects;
- Sales and marketing practices, including product launches and shortages proceedings;
- General regulatory matters – interactions with healthcare practitioners; educational and research grants; scientific events and similar activities; free products; samples; gifts and other business courtesies etc;
- Advertising and promotion practices and compliance with professional/industry ethics – Social Media content review;
- Labeling and packaging practices;
- Clinical trial implementation and other research and development activities;
- Market Researches;
- Pharmaceutical cannabis regulation;
- Assistance in implementation of patient programs;
- Digital health – experience on issues involving the new methods of health information delivery; internet platforms and mobile apps;
- E-Commerce and Internet Policies;
- Privacy and Data Protection;
- Intellectual Property;
- Competition – Pharmaceutical Antitrust – Dawn raid awareness and preparedness training courses;
- Parallel Import/Export activities;
- Compliance Programs – development and implementation of standard operation and anti-corruption policies;
- Corporate compliance programs – development and implementation of corporate compliance programs and audits;
- Public tenders and awards – preparation and processing of files and documents for public tender procedures, representation in court proceedings – attending negotiation procedures with public authorities regards supplied of NHS hospitals;
- Regulatory agency processes/public policy issues;
- Product Liability – strategic handling and assessment, including litigation;
We represent national and international companies in disputes covering the full range of industry operations, including:
- Contract disputes;
- Termination of distribution agreements;
- Collections from hospitals;
- Infringement of intellectual property rights;
- Product liability cases;
- Imposition of administrative fines by local authorities;
- Imposition of clawback and rebates;
- Recourses against State decisions.
Featured
KG Supported the 25th HealthWorld Conference
September 16, 2026
KG Authors the Greece Chapter of ICLG – Pharmaceutical Advertising 2026
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou, Christos Christodoulou, Theodora Fesatidou | August 6, 2026
Doing Business in Greece 2026: Key Legal Considerations
BY Anastasia Dritsa, Vasiliki (Vicky) Kriketou, Irene Kyriakides, Ioanna Kyriazi, Dr. Victoria Mertikopoulou, Kleoniki-Maria (Claire) Pavlou, Panagiotis Pothos | July 31, 2026
Law 5317/2026: New Greek Anti-Greenwashing Rules: What Businesses Need to Know
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou, Theodora Fesatidou | July 30, 2026
Greece Introduces New Rules for Cannabis Products under Law 5322/2026
BY Irene Kyriakides, Aithra Valentina Antoniadou, Theodora Fesatidou | July 29, 2026
Law 5302/2026 for the Establishment of an Innovation Fund, Patient Access to New Medicines and Treatments, Improvement of Health Services and Other Provisions
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou, Christos Christodoulou, Theodora Fesatidou | May 26, 2026
KG’s Life Sciences and Healthcare Team joined the EU Pharmaceutical Law Forum 2026
BY Aithra Valentina Antoniadou, Irene Kyriakides, Dr. Victoria Mertikopoulou | May 22, 2026
From regulatory change to real-world risk: the conversations shaping the future of Pharma are happening in Brussels this May
BY Aithra Valentina Antoniadou | May 11, 2026
Joint Ministerial Decision on Clawback Set-Off Against R&D and Investment Expenditures for 2026-2027
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou, Christos Christodoulou, Theodora Fesatidou | April 14, 2026
KG has been shortlisted for Greece Firm of the Year on the LMG Life Sciences EMEA Awards 2026
March 27, 2026
KG Acted as Greek Counsel on Medtronic Diabetes Business Carve-Out and MiniMed IPO
BY Konstantinos Vouterakos, Vasileios P. Douzenis, Kelly Papadaki, Ioanna Chanoumi, Irene Kyriakides, Aithra Valentina Antoniadou, Dr. Victoria Mertikopoulou, Ifigeneia Argyri | March 19, 2026
Joint Ministerial Decision for the Simplification of Clinical Research Issued: Overview of Key Changes in Clinical Research Contracting in Greece
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou, Christos Christodoulou | February 2, 2026
Simplification and rationalisation of contracting and financial management procedures
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | January 26, 2026
KG at 1st Panhellenic Student Conference on Legal Informatics -University of Athens Legal Tech Society, and Law & Invisible Risks – ELSA GREECE
BY Aithra Valentina Antoniadou, Apostolos Papachrysos, Nikolaos – Tilemachos Vellios | December 19, 2025
𝐏𝐫𝐨𝐮𝐝 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐞𝐫𝐬 𝐨𝐟 𝐥𝐞𝐠𝐚𝐥 𝐭𝐞𝐜𝐡 𝐞𝐝𝐮𝐜𝐚𝐭𝐢𝐨𝐧!
BY Aithra Valentina Antoniadou, Apostolos Papachrysos, Nikolaos – Tilemachos Vellios | December 10, 2025
New MD on Individual Distribution of High-Cost Medicines: What It Really Changes
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Christos Christodoulou | December 9, 2025
Updates on EU Simplification Rules
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Athanasia Voyadzis | December 2, 2025
Unique Device Identifier
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | November 17, 2025
Reporting Obligations for Veterinary Medicinal Products: Implementation of Regulation (EU) 2019/6 and EOF’s Recent Announcement
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aspa Marinaki | November 14, 2025
𝐇𝐨𝐰 𝐜𝐚𝐧 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐜𝐨𝐧𝐟𝐢𝐝𝐞𝐧𝐭𝐥𝐲 𝐧𝐚𝐯𝐢𝐠𝐚𝐭𝐞 𝐭𝐡𝐞 𝐜𝐨𝐦𝐩𝐥𝐞𝐱 𝐆𝐫𝐞𝐞𝐤 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐥𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐨𝐧 𝐚𝐝𝐯𝐞𝐫𝐭𝐢𝐬𝐢𝐧𝐠 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐚𝐥 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐬?
BY Irene Kyriakides, Aithra Valentina Antoniadou | August 8, 2025
New Regulatory Framework Governing University HCPs’ Engagement in the Private Sector
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | July 18, 2025
Revised Code of Ethics issued by the Hellenic Association of Pharmaceutical Companies
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | June 30, 2025
Greece’s ESG Landscape: Legal 500 Chapter by KG Law Firm
BY Irene Kyriakides | June 2, 2025
New Circular on Scientific Events
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | April 23, 2025
New Framework in Greece to Combat Falsified Medicines and Protect Public Health
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | March 17, 2025
Rebate Strategies for Medical Devices procured by Public Hospitals
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | March 14, 2025
The European Commission has published the Omnibus Proposal. What does that mean for CSRD and CSDDD compliance?
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | March 4, 2025
Entry into force of Regulation (EU) 2025/40 on packaging and packaging waste
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | February 18, 2025
New Unique Code Requirement for Medicinal Products in Greece
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | February 6, 2025
Adoption of Law 5164/2024 transposing the CSRD into Greek Law
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | December 18, 2024
Urgent Action Required: HMVO Registration Deadline Approaching – Compliance by February 9, 2025!
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | November 29, 2024
Regulation on Packaging and Packaging Waste
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | November 12, 2024
Adoption of the final text of the Corporate Sustainability Due Diligence Directive (CSDDD)
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | November 12, 2024
ICLG – Pharmaceutical Advertising 2024
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | August 12, 2024
Shipments of Waste
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | July 25, 2024
Artificial Intelligence (AI) and the Healthcare Industry
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | July 24, 2024
Greek Council of State upholds constitutionality of clawback post COVID-19
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Constantinos Kavadellas, Georgia Panagopoulou, Aithra Valentina Antoniadou | June 26, 2024
New proposed rules for the chemical industry on classification, labelling and packaging of substances and mixtures
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | June 26, 2024
Revised Q&A on Combinations of Medicinal Products and Medical Devices
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | June 18, 2024
Law 5102/2024: Public Measures – Regulations for Strengthening the National Healthcare System
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | May 29, 2024
EU joins the fight against greenwashing by proposing new rules for green claims
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | April 17, 2024
Revision of the Framework on Medicines Pricing
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | March 27, 2024
Draft Implementing Act HTA Regulation
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | March 7, 2024
Newsflash EOF Circular
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | March 6, 2024
Cannabis News: Reclassification of hexahydrocannabinol (HHC)-containing products as narcotics under state control and withdrawal from all accessible points of sale.
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | January 23, 2024
New obligations and penalties for importing goods into the EU: Introducing the Carbon Border Adjustment Mechanism (“CBAM”) to combat climate change.
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | November 2, 2023
MSSG Toolkit and Solidarity Mechanism for Medicines Shortages
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | October 25, 2023
Reflection Paper on the use of Artificial Intelligence in the medicinal products lifecycle
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | August 29, 2023
Change in the limit for HCPs participation in online and hybrid scientific events organized abroad
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | August 3, 2023
Pharmaceutical Advertising and Regulations 2023
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | July 14, 2023
3rd Health & Compliance Forum
BY Constantinos Kavadellas | July 3, 2023
MDCG 2020-3 Rev.1: Updates to MDR Significant Changes
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | June 28, 2023
Single-use plastic beverage bottles: EU rules for calculating verifying and reporting on recycled plastic content
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | June 21, 2023
Chemicals – Simplification and digitalization of labelling requirements
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | June 21, 2023
Good Practices for Industry for the Prevention of Human Medicinal Product Shortages
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | June 12, 2023
Hospital at Home Treatment and Healthcare
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | June 12, 2023
Proposal for a Directive on Green Claims
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | June 9, 2023
Tobacco Product Traceability
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | December 12, 2022
Medical Devices – What’s new?
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | December 12, 2022
Law 4931/2022 “Doctor for All, Equal and Quality Access to the Services of the National Services Health Organization (EOPYY) and Primary Health Care and other emergency provisions”
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | December 12, 2022
Responsibilities of Authorized Representatives in light of MDCG 2022-16 Guidance
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | December 12, 2022
2nd Law and Health Policies Conference
BY Vasiliki (Vicky) Kriketou | October 17, 2022
EMA and HMA Joint Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | September 23, 2022
Proud contributors to the Pharmaceutical Advertising 2022 guide published by ICLG
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | July 8, 2022
MedTech Europe Code of Ethical Business Practice: March 2022 New Version (part b)
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | May 24, 2022
MedTech Europe Code of Ethical Business Practice: March 2022 New Version (part a)
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | May 24, 2022
Joint Guidance on Virtual and Hybrid International Medical Congresses
BY Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | May 24, 2022
Public Consultation of the Draft Law “Doctor for All, Equal and Quality Access to the Services of the National Services Health Organization (EOPYY) and Primary Health Care and other provisions”
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | April 14, 2022
The Clinical Trials Regulation (EU) 536/2014 (“CTR”) finally enters into application
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | February 16, 2022
Regulation (EU) 2019/6 on veterinary medicinal products enters into application
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | February 1, 2022
Public Consultation on common specifications for products without an intended medical purpose under the MDR
BY Irene Kyriakides | January 28, 2022
Health and Food Law developments in 2021
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | December 29, 2021
Medical Update
October 12, 2021
Law 4819/2021 transposing Directive (EU) 2018/852 on packaging and packaging waste
BY Irene Kyriakides, Constantinos Kavadellas, Aithra Valentina Antoniadou | September 9, 2021
Law 4819/2021 transposing Directive (EU) 2018/851 on waste
BY Irene Kyriakides, Constantinos Kavadellas, Aithra Valentina Antoniadou | September 7, 2021
Hellenic Competition Commission sector inquiry into the provision of private healthcare and related insurance services: The HCC focuses on the interplay between Big Data and the private health care sector
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Ifigeneia Argyri | July 27, 2021
Proud contributors to the Pharmaceutical Advertising 2021 guide published by ICLG
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | July 26, 2021
EOF issues Notice and relevant Q&A memo regarding the advertising of pharmaceutical products
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | May 27, 2021
Pharma & Healthcare Procurement: Top-10 changes affecting healthcare industry regarding the new Law 4782/2021 on reforming public procurement in Greece
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | May 24, 2021
The Medical Devices Regulation (EU) 2017/745 (MDR) finally enters into application – Are you ready?
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | May 6, 2021
Life after Brexit: A brief estimation of particular issues raised in Greece in the pharmaceuticals sector following the December 2020 Trade Agreement.
BY Irene Kyriakides | April 19, 2021
Custom-Made Devices: Medical Device Coordination Group (MDCG) Clarifications
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | March 26, 2021
Electronic Product Information (“ePI”): Industry Views on Regulatory Issues
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | March 16, 2021
Excessive pricing in the Pharma sector on the spotlight: The European Commission makes legally binding Aspen’s price commitments
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Ifigeneia Argyri | March 8, 2021
The International Comparative Legal Guide – Digital Health 2021
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | March 2, 2021
Joint Ministerial Decision on the establishment of the ‘Hellenic Medicines Verification Organization’
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Ifigeneia Argyri | February 15, 2021
Final Version of SFEE’s Code of Ethics
BY Irene Kyriakides, Dr. Victoria Mertikopoulou, Aithra Valentina Antoniadou | September 22, 2020
Newly Revised SFEE’s Code of Ethics
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | July 29, 2020
Recent EOF Circular on Scientific Events
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | April 2, 2020
Proud contributors to the Digital Health 2020 guide published by ICLG
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | March 25, 2020
New price controls provisions and HCC investigation regarding price increases and shortages in healthcare materials
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | March 22, 2020
Liberalization in the Pharmacy Sector
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | March 18, 2020
Reduced rate (6%) for Products and Services Provided to Patients Suffering from Refractory Diseases: a Significant Amendment of the Ministry of Finance
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | March 18, 2020
Joint Ministerial Decision includes pharmaceutical R&D projects and investment plans expenses to the clawback set-off
BY Irene Kyriakides, Dr. Victoria Mertikopoulou | March 18, 2020
Implementation of the Medical Devices Regulation (EU) 2017/745 (MDR)
BY Irene Kyriakides, Aithra Valentina Antoniadou | January 21, 2020
The Council of State annuls a clawback imposition for first time: “The Orphans case”
BY Irene Kyriakides, Constantinos Kavadellas | November 1, 2019
Patent infringement and litigation (April 2019)
BY Irene Kyriakides | October 2, 2019
Cross usage of medical devices (September 2019)
BY Irene Kyriakides | October 2, 2019
Internal compliance in the medical devices industry (July 2019)
BY Irene Kyriakides | October 2, 2019
Food for special purposes (medical use) (June –September 2019)
BY Irene Kyriakides | October 2, 2019
Tobacco industry (March 2019)
BY Irene Kyriakides | October 2, 2019
New Generation Products (NGPs) to hit Greece (May 2019)
BY Irene Kyriakides | October 2, 2019
Transfer of business in the cosmetics sector (August 2019)
BY Irene Kyriakides | October 2, 2019
Pharma entry negotiations (June 2019)
BY Irene Kyriakides | October 2, 2019
Distribution practices in the pharmaceutical sector (June 2019)
BY Irene Kyriakides | October 2, 2019
Pharmaceutical distribution and co-promotion (May 2019)
BY Irene Kyriakides | October 2, 2019
Cannabis investors create a new EU hub in Greece (January – September 2019)
BY Irene Kyriakides | October 2, 2019
NewsFlash on the Ministry of Health Circular Ref. No. Γ5α/Γ.Π.οικ 46754
BY Irene Kyriakides | July 2, 2019
Pricing of Pharmaceutical Products | Rebates for the Years 2006, 2007 and 2008
BY Irene Kyriakides | May 27, 2019
Medicinal Cannabis in Greece
December 14, 2018
A World Leading Pharmaceutical Company
BY Constantinos Kavadellas, Irene Kyriakides | November 12, 2018
New Committee | New Fees for Pharma Companies
BY Irene Kyriakides | September 24, 2018
Clinical Trials in Greece
BY Irene Kyriakides | June 19, 2018
Life Sciences: Product Regulation and Liability in Greece
BY Irene Kyriakides | May 21, 2018
World Leading Food Company
BY Irene Kyriakides | May 15, 2018
Medical Devices Company
BY Irene Kyriakides | May 7, 2018
Healthcare Company
BY Irene Kyriakides | April 10, 2018
Major Changes in the Medical World – How Law 4512/2018 Will Shape the Pharma Industry?
BY Irene Kyriakides | February 21, 2018
World Leading Pharmaceutical Company
BY Irene Kyriakides | February 6, 2018
Major pharma companies
BY Irene Kyriakides | February 6, 2018
Medicinal Product Liability: Adverse Drug Reactions and Insufficient Product Information
BY Vasiliki (Vicky) Kriketou | January 22, 2018
Global Leader in the Manufacture of Musculoskeletal Medical Products
BY Irene Kyriakides | November 9, 2017
New provisions of Law 4472/2017 regarding the Greek Healthcare Sector
BY Irene Kyriakides | June 26, 2017
Pharmaceutical Advertising 2017
BY Irene Kyriakides | June 8, 2017
Pharmacovigilance in Greece | Q&A
BY Irene Kyriakides | June 6, 2017
Life Sciences
May 15, 2017
Production, Circulation and Pricing of Drugs-Brand Name and Generic
BY Irene Kyriakides | May 15, 2017
Life Sciences: Product Regulation and Liability
BY Irene Kyriakides | April 28, 2017
Promotion of Medicinal Products
BY Irene Kyriakides | April 12, 2017
Research-based Biopharmaceutical Company
BY Irene Kyriakides | November 2, 2016
The International Comparative Legal Guide to: Pharmaceutical Advertising 2016
BY Irene Kyriakides | June 24, 2016
Pharmaceutical
BY Irene Kyriakides | September 19, 2013
Pharmaceutical Updates | Summer 2013
BY Irene Kyriakides | July 31, 2013
Pharmaceutical
BY Irene Kyriakides | October 16, 2012
Getting the Deal Through – Pharmaceutical Antitrust 2012
BY Anastasia Dritsa | April 16, 2012
“Life Sciences” Greek Law Digest Investor’s Guide
BY Irene Kyriakides | January 3, 2012
